Evidence map›Paper›PMID 10233704›Full record

ArticleImmunology1999

Lymphocyte-specific protein 1: a specific marker of human leucocytes.

K Pulford, M Jones, A H Banham, E Haralambieva, D Y Mason

Open access · greenAbstract read
In one paragraph

Article in Immunology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Leukocyte-specific protein 1 regulates T-cell migration in rheumatoid arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  18. Leukocyte-specific protein 1 regulates neutrophil recruitment in acute lung inflammation.American journal of physiology. Lung cellular and molecular physiology · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

K PulfordLeukaemia Research Fund Immunodiagnostics Unit, Nuffield Department of Clinical Biochemistry and Cellular Science, John Radcliffe Hospital, Oxford, UK.
M Jones
A H Banham
E Haralambieva
D Y Mason
John Radcliffe Hospital · GBBlood Cancer UK · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While both murine and human homologues of the LSP1 gene (lymphocyte-specific gene 1) and its protein products have been identified, studies on human LSP1 have been limited. The present report describes a detailed immunocytochemical study of the distribution and localization of human LSP1 in both normal and neoplastic cells and tissues. The specificity of the monoclonal anti-LSP1 reagent was confirmed by expression cloning and transfection studies. The intracellular 60 000 MW LSP1 protein was found to be present in peripheral blood B cells, monocytes and granulocytes but absent in a subpopulation of circulating T cells (10-15% of CD3-positive T cells). The presence of LSP1 protein in medullary thymocytes, but only in scattered cortical thymocytes, provided additional evidence for heterogeneity of expression in T cells. Novel observations also included the presence of LSP1 in plasma cells, dendritic cells and Langerhans' cells. The leucocyte-restricted distribution of LSP1 protein means that it may play an important role in haematopathology. LSP1 protein was detected in a wide range of leukaemias and lymphomas, particularly of B-cell origin, and in tumour cells in classical Hodgkin's disease. Of interest was the indication of a reciprocal relationship in the expression of LSP1 and ALK (anaplastic lymphoma kinase) proteins in patients with anaplastic large cell lymphoma. As the anti-LSP1 reagent used in the present study recognizes a formalin-resistant epitope it should be of considerable value in the diagnosis of routinely fixed material.

Indexed as

Anaplastic Lymphoma KinaseBiomarkersBlotting, WesternB-LymphocytesCell LineDendritic CellsGranulocytesHodgkin DiseaseHumansImmunohistochemistryLangerhans CellsLeukemiaLeukocytesLymphomaLymphoma, Large B-Cell, DiffuseMonocytesALK protein, humanAnaplastic Lymphoma KinaseBiomarkerslymphocyte-specific protein p50PhosphoproteinsProtein-Tyrosine KinasesReceptor Protein-Tyrosine Kinases

Identifiers

PMID10233704
PMCPMC2326732
OpenAlexW2054583078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.